Regulatory Approval

Regulatory Approval

Eco Animal Health Group Plc

ECO Animal Health Group plc (ECO)

(AIM:EAH)

ECO RECEIVES FIRST MARKETING AUTHORISATION FOR AIVLOSIN® IN RUSSIA

ECO is pleased to report that the Ministry of Agriculture of the Russian Federation has granted ECO a marketing authorisation for Aivlosin® 42.5 mg/g premix for swine.

Russia is the seventh largest pork producing country and it has seen a 50 per cent growth in pork production between 2006 and 2011 driven by both domestic demand and import substitution, with growing adoption of large scale, intensive production techniques. This initial and very important Russian authorisation comes just four months after the US Food and Drug Administration granted ECO its first marketing authorisation in the United States for Aivlosin^® 625 mg/g water soluble granules for swine. Aivlosin®, ECO’s patented macrolide antibiotic, is used for the treatment of respiratory and enteric (gut) diseases in pigs and poultry.

Peter Lawrence, Chairman of ECO, commented “This latest authorisation in Russia is another extremely encouraging and positive step in the development of Aivlosin® as a truly global brand and underlines ECO’s commitment to becoming a major force in the international market for veterinary pharmaceutical products.”

Contacts:

ECO Animal Health Group plc	Â
Peter Lawrence		020 8336 6190
Â
Spiro Financial
Anthony Spiro		020 8336 6196
Â
Cenkos Securities plc (Nominated Adviser)
Stephen Keys		020 7397 8926

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.